The ability of a mixed CCKA/B receptor antagonist
PD 142898 (benzenebutanic
acid, beta-[[3-(1 H-indol-3-yl)-2-methyl-2-[[[(2-methyl- cyclohexyl)oxy]carbonyl]amino]-1-oxopropyl]amino]-[1 S-[1 alpha [S*(R*)]-2 beta]]) to modulate the antinociceptive, positive reinforcing and gastrointestinal actions of
morphine was investigated in the rat.
PD 142898 antagonised the development and maintenance of
morphine (2.0 mg/kg, s.c.) induced conditioned place preference at 0.1 mg/kg, i.p. However, it potentiated the antinociceptive action of a subthreshold dose of
morphine in the radiant tail flick model at doses of 0.001 and 0.01 mg/kg, s.c. Furthermore,
PD 142898 (0.0001-1.0 mg/kg, s.c.) also potentiated the antinociceptive action of
morphine (1.0 mg/kg, s.c.) against the late phase of
formalin response associated with
inflammation at the dose of 0.001-1.0 mg/kg.
PD 142898 (0.001 mg/kg, s.c.) blocked the development of tolerance to
morphine in the
formalin test. It failed (0.001-1.0 mg/kg, i.p.) to modulate the inhibitory action of
morphine (5.0 mg/kg, s.c.) on gastrointestinal transit as measured using the
charcoal meal test. It is argued that the effect of
PD 142898 in the conditioned place preference test involves antagonism of CCKA receptors, whilst the potentiation of the antinociceptive action of
morphine is mediated via blockade of CCKB receptors. These results suggest that the mixed CCKA/B receptor antagonist may potentiate the
analgesic action of
morphine, block the development of tolerance without a concomitant increase in
constipation and may also reduce the abuse potential of the
opiate.